Nature Communications · 2024 · 33 citations · 75 references
MedicineImmunologyOncologyCancer ImmunologyTumor ImmunologyTumor MicroenvironmentAntitumor T Cell ResponsesCancer ImmunotherapyChimeric Antigen Receptor T-cell TherapyImmunotherapy For Solid TumorsInnate Immune ActivationT Cell Responses To TumorsAntigen Escape MechanismsBispecific Cell Engager DesignBispecific Natural Killer Cell EngagersInnate Antitumor ImmunityNeuroblastoma BiologySolid Tumor Car T-cell TherapyTumor Microenvironment EffectsTumor-associated Antigen Targeting
Novel chimeric antigen receptor (CAR) T-cell approaches are needed to improve therapeutic efficacy in solid tumors. High-risk neuroblastoma is an aggressive pediatric solid tumor that expresses cell-surface GPC2 and GD2 with a tumor microenvironment infiltrated by CD16a-expressing innate immune cells. Here we engineer T-cells to express a GPC2-directed CAR and simultaneously secrete a bispecific innate immune cell engager (BiCE) targeting both GD2 and CD16a. In vitro, GPC2.CAR-GD2.BiCE T-cells induce GPC2-dependent cytotoxicity and secrete GD2.BiCE that promotes GD2-dependent activation of antitumor innate immunity. In vivo, GPC2.CAR-GD2.BiCE T-cells locally deliver GD2.BiCE and increase intratumor retention of NK-cells. In mice bearing neuroblastoma patient-derived xenografts and reconstituted with human CD16a-expressing immune cells, GD2.BiCEs enhance GPC2.CAR antitumor efficacy. A CAR.BiCE strategy should be considered for tumor histologies where antigen escape limits CAR efficacy, especially for solid tumors like neuroblastoma that are infiltrated by innate immune cells. GPC2 and GD2 have been described as immunotherapeutic targets in neuroblastoma. Here the authors engineer T cells to simultaneously express a GPC2-directed CAR and a bispecific innate immune cell engager targeting GD2 and CD16a, showing antitumor activity in neuroblastoma preclinical models.
75
Integrated analysis of multimodal single-cell data
Yuhan Hao, Stephanie Hao, Erica Andersen‐Nissen et al. · Cell · 2021 · 16K citations · Full text
Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia
Shannon L. Maude, Theodore W. Laetsch, Jochen Buechner et al. · New England Journal of Medicine · 2018 · 5.6K citations · Full text
Medicine, Hematology, Oncology +17
Anti-GD2 Antibody with GM-CSF, Interleukin-2, and Isotretinoin for Neuroblastoma
Alice L. Yu, Andrew L. Gilman, M. Fevzi Özkaynak et al. · New England Journal of Medicine · 2010 · 1.8K citations · Full text
Medicine, Immunology, Oncology +14
Donald M. O’Rourke, MacLean P. Nasrallah, Arati Desai et al. · Science Translational Medicine · 2017 · 1.8K citations · Full text
Medicine, Immunology, Oncology +17